India's Jubilant Pharmova reported a surge in its fourth-quarter adjusted profit on Friday, driven by strong demand for its drugs with radioactive ingredients, used to treat cancer and other diseases.

Other than that, nothing,” says the 69-year-old chairman and managing director of Sun Pharma, India’s largest pharmaceutical company ... for advanced skin cancer—a high-value therapy.

Smaller pharma companies in India comply with the World Health Organization ... drugs are set to expire in 2025-2026, including cancer immunotherapy drug Keytruda developed by Merck, Ozempic ...

Several of the top pharmaceutical companies ... oncology medicines are affordable, according to Prof Anil D'Cruz, president of UICC and director of oncology at the Apollo Hospitals group in India.

Mark Baldridge is an assistant professor of fine art and computer science at Albright College teaching in the game and ...

New Delhi: Indian pharmaceutical companies are ramping up efforts to expand their footprint in the lucrative US oncology generics ... of Pharmaceuticals, India’s pharmaceutical and medical ...

Gland Pharma ... company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. The company has 8 manufacturing facilities in India ...

So, when a life sciences company embarks on a project of digital ... area at Biogen Digital Health is digital therapeutics and other pharma-adjacent interventions. Hadjiat draws a distinction ...

Pharmaceutical ... India. IMPACT ON R&D Bill Coyle, head of biopharma at consulting firm ZS, said drugmakers will try to pass on tariff costs, but because many categories are very competitive, "the ...

O n this episode of Fortune’s Leadership Next podcast, cohosts Diane Brady, executive editorial director of the Fortune CEO Initiative and Fortune Live Media, and editorial dire ...

Christopher Groux is an editor, writer and accessibility advocate. Before joining the Forbes Health team, he covered Accessibility at Reviewed and gaming at Inverse and Newsweek. When he’s not ...